Does the media favor SLS or SLN?

In the previous week, Silence Therapeutics had 5 more articles in the media than SELLAS Life Sciences Group. MarketBeat recorded 15 mentions for Silence Therapeutics and 10 mentions for SELLAS Life Sciences Group. Silence Therapeutics' average media sentiment score of 0.84 beat SELLAS Life Sciences Group's score of 0.60 indicating that Silence Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SELLAS Life Sciences Group 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Silence Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor KOD or SLN?

In the previous week, Kodiak Sciences had 3 more articles in the media than Silence Therapeutics. MarketBeat recorded 18 mentions for Kodiak Sciences and 15 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 0.84 beat Kodiak Sciences' score of 0.10 indicating that Silence Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kodiak Sciences 5 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Silence Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer RARE or SLN?

In the previous week, Ultragenyx Pharmaceutical had 17 more articles in the media than Silence Therapeutics. MarketBeat recorded 32 mentions for Ultragenyx Pharmaceutical and 15 mentions for Silence Therapeutics. Ultragenyx Pharmaceutical's average media sentiment score of 0.98 beat Silence Therapeutics' score of 0.84 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ultragenyx Pharmaceutical 20 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Silence Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to SLN or NKTR?

In the previous week, Nektar Therapeutics had 5 more articles in the media than Silence Therapeutics. MarketBeat recorded 20 mentions for Nektar Therapeutics and 15 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 0.84 beat Nektar Therapeutics' score of 0.44 indicating that Silence Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Silence Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nektar Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer BCRX or SLN?

In the previous week, Silence Therapeutics had 11 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 15 mentions for Silence Therapeutics and 4 mentions for BioCryst Pharmaceuticals. BioCryst Pharmaceuticals' average media sentiment score of 1.01 beat Silence Therapeutics' score of 0.84 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioCryst Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Silence Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Silence Therapeutics (SLN) Competitors

$13.47 +0.20 (+1.48%)

As of 02:46 PM Eastern

Compare

SLN vs. SLS, KOD, RARE, NKTR, and BCRX

Should you buy Silence Therapeutics stock or one of its competitors? Silence Therapeutics's main competitors and comparable companies include SELLAS Life Sciences Group (SLS), Kodiak Sciences (KOD), Ultragenyx Pharmaceutical (RARE), Nektar Therapeutics (NKTR), and BioCryst Pharmaceuticals (BCRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Silence Therapeutics compare to SELLAS Life Sciences Group?

SELLAS Life Sciences Group (NASDAQ:SLS) and Silence Therapeutics (NASDAQ:SLN) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, earnings, institutional ownership, dividends, valuation and risk.

SELLAS Life Sciences Group has a net margin of 0.00% compared to Silence Therapeutics' net margin of -8,943.86%. SELLAS Life Sciences Group's return on equity of -35.91% beat Silence Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SELLAS Life Sciences Group	N/A	-35.91%	-33.34%
Silence Therapeutics	-8,943.86%	-106.94%	-47.99%

In the previous week, Silence Therapeutics had 5 more articles in the media than SELLAS Life Sciences Group. MarketBeat recorded 15 mentions for Silence Therapeutics and 10 mentions for SELLAS Life Sciences Group. Silence Therapeutics' average media sentiment score of 0.84 beat SELLAS Life Sciences Group's score of 0.60 indicating that Silence Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SELLAS Life Sciences Group	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Silence Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

SELLAS Life Sciences Group has higher earnings, but lower revenue than Silence Therapeutics. SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SELLAS Life Sciences Group	N/A	N/A	-$26.86M	-$0.21	N/A
Silence Therapeutics	$615K	1,034.59	-$88.61M	-$1.28	N/A

SELLAS Life Sciences Group presently has a consensus target price of $10.00, indicating a potential downside of 30.39%. Silence Therapeutics has a consensus target price of $53.50, indicating a potential upside of 297.27%. Given Silence Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Silence Therapeutics is more favorable than SELLAS Life Sciences Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SELLAS Life Sciences Group	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

SELLAS Life Sciences Group has a beta of 2.48, suggesting that its share price is 148% more volatile than the broader market. Comparatively, Silence Therapeutics has a beta of 1.39, suggesting that its share price is 39% more volatile than the broader market.

17.4% of SELLAS Life Sciences Group shares are owned by institutional investors. Comparatively, 98.7% of Silence Therapeutics shares are owned by institutional investors. 1.3% of SELLAS Life Sciences Group shares are owned by company insiders. Comparatively, 3.0% of Silence Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Silence Therapeutics beats SELLAS Life Sciences Group on 10 of the 16 factors compared between the two stocks.

How does Silence Therapeutics compare to Kodiak Sciences?

Kodiak Sciences (NASDAQ:KOD) and Silence Therapeutics (NASDAQ:SLN) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, media sentiment, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

Kodiak Sciences currently has a consensus price target of $48.14, suggesting a potential upside of 29.87%. Silence Therapeutics has a consensus price target of $53.50, suggesting a potential upside of 297.27%. Given Silence Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Silence Therapeutics is more favorable than Kodiak Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

89.1% of Kodiak Sciences shares are owned by institutional investors. Comparatively, 98.7% of Silence Therapeutics shares are owned by institutional investors. 44.4% of Kodiak Sciences shares are owned by company insiders. Comparatively, 3.0% of Silence Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Kodiak Sciences had 3 more articles in the media than Silence Therapeutics. MarketBeat recorded 18 mentions for Kodiak Sciences and 15 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 0.84 beat Kodiak Sciences' score of 0.10 indicating that Silence Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kodiak Sciences	5 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Silence Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kodiak Sciences has a net margin of 0.00% compared to Silence Therapeutics' net margin of -8,943.86%. Silence Therapeutics' return on equity of -106.94% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kodiak Sciences	N/A	-273.23%	-85.48%
Silence Therapeutics	-8,943.86%	-106.94%	-47.99%

Silence Therapeutics has higher revenue and earnings than Kodiak Sciences. Silence Therapeutics is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.19	N/A
Silence Therapeutics	$615K	1,034.59	-$88.61M	-$1.28	N/A

Kodiak Sciences has a beta of 2.21, suggesting that its stock price is 121% more volatile than the broader market. Comparatively, Silence Therapeutics has a beta of 1.39, suggesting that its stock price is 39% more volatile than the broader market.

Summary

Silence Therapeutics beats Kodiak Sciences on 10 of the 16 factors compared between the two stocks.

How does Silence Therapeutics compare to Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical (NASDAQ:RARE) and Silence Therapeutics (NASDAQ:SLN) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, media sentiment, earnings, valuation, risk and analyst recommendations.

Silence Therapeutics has lower revenue, but higher earnings than Ultragenyx Pharmaceutical. Silence Therapeutics is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ultragenyx Pharmaceutical	$673M	3.78	-$575M	-$5.84	N/A
Silence Therapeutics	$615K	1,034.59	-$88.61M	-$1.28	N/A

Ultragenyx Pharmaceutical has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market. Comparatively, Silence Therapeutics has a beta of 1.39, suggesting that its stock price is 39% more volatile than the broader market.

Ultragenyx Pharmaceutical presently has a consensus price target of $58.89, indicating a potential upside of 128.07%. Silence Therapeutics has a consensus price target of $53.50, indicating a potential upside of 297.27%. Given Silence Therapeutics' higher probable upside, analysts plainly believe Silence Therapeutics is more favorable than Ultragenyx Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.84
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. Comparatively, 98.7% of Silence Therapeutics shares are held by institutional investors. 5.2% of Ultragenyx Pharmaceutical shares are held by insiders. Comparatively, 3.0% of Silence Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Ultragenyx Pharmaceutical had 17 more articles in the media than Silence Therapeutics. MarketBeat recorded 32 mentions for Ultragenyx Pharmaceutical and 15 mentions for Silence Therapeutics. Ultragenyx Pharmaceutical's average media sentiment score of 0.98 beat Silence Therapeutics' score of 0.84 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ultragenyx Pharmaceutical	20 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Silence Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ultragenyx Pharmaceutical has a net margin of -81.79% compared to Silence Therapeutics' net margin of -8,943.86%. Silence Therapeutics' return on equity of -106.94% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ultragenyx Pharmaceutical	-81.79%	-1,024.42%	-44.40%
Silence Therapeutics	-8,943.86%	-106.94%	-47.99%

Summary

Ultragenyx Pharmaceutical beats Silence Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Silence Therapeutics compare to Nektar Therapeutics?

Silence Therapeutics (NASDAQ:SLN) and Nektar Therapeutics (NASDAQ:NKTR) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

Silence Therapeutics has a beta of 1.39, indicating that its share price is 39% more volatile than the broader market. Comparatively, Nektar Therapeutics has a beta of 1.14, indicating that its share price is 14% more volatile than the broader market.

Silence Therapeutics has higher earnings, but lower revenue than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silence Therapeutics	$615K	1,034.59	-$88.61M	-$1.28	N/A
Nektar Therapeutics	$55.23M	45.89	-$164.08M	-$6.70	N/A

98.7% of Silence Therapeutics shares are held by institutional investors. Comparatively, 75.9% of Nektar Therapeutics shares are held by institutional investors. 3.0% of Silence Therapeutics shares are held by company insiders. Comparatively, 2.5% of Nektar Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Nektar Therapeutics had 5 more articles in the media than Silence Therapeutics. MarketBeat recorded 20 mentions for Nektar Therapeutics and 15 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 0.84 beat Nektar Therapeutics' score of 0.44 indicating that Silence Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Silence Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nektar Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Nektar Therapeutics has a net margin of -287.84% compared to Silence Therapeutics' net margin of -8,943.86%. Nektar Therapeutics' return on equity of -37.87% beat Silence Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silence Therapeutics	-8,943.86%	-106.94%	-47.99%
Nektar Therapeutics	-287.84%	-37.87%	-25.67%

Silence Therapeutics currently has a consensus price target of $53.50, suggesting a potential upside of 297.27%. Nektar Therapeutics has a consensus price target of $141.50, suggesting a potential upside of 90.60%. Given Silence Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Silence Therapeutics is more favorable than Nektar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Nektar Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

Summary

Silence Therapeutics beats Nektar Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Silence Therapeutics compare to BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals (NASDAQ:BCRX) and Silence Therapeutics (NASDAQ:SLN) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation, media sentiment and analyst recommendations.

BioCryst Pharmaceuticals has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market. Comparatively, Silence Therapeutics has a beta of 1.39, suggesting that its stock price is 39% more volatile than the broader market.

85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. Comparatively, 98.7% of Silence Therapeutics shares are owned by institutional investors. 3.8% of BioCryst Pharmaceuticals shares are owned by company insiders. Comparatively, 3.0% of Silence Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

BioCryst Pharmaceuticals has higher revenue and earnings than Silence Therapeutics. Silence Therapeutics is trading at a lower price-to-earnings ratio than BioCryst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCryst Pharmaceuticals	$874.84M	2.83	$263.86M	-$1.50	N/A
Silence Therapeutics	$615K	1,034.59	-$88.61M	-$1.28	N/A

In the previous week, Silence Therapeutics had 11 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 15 mentions for Silence Therapeutics and 4 mentions for BioCryst Pharmaceuticals. BioCryst Pharmaceuticals' average media sentiment score of 1.01 beat Silence Therapeutics' score of 0.84 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioCryst Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Silence Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioCryst Pharmaceuticals currently has a consensus target price of $20.60, indicating a potential upside of 112.92%. Silence Therapeutics has a consensus target price of $53.50, indicating a potential upside of 297.27%. Given Silence Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Silence Therapeutics is more favorable than BioCryst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCryst Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.67
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

BioCryst Pharmaceuticals has a net margin of -40.90% compared to Silence Therapeutics' net margin of -8,943.86%. BioCryst Pharmaceuticals' return on equity of -86.89% beat Silence Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCryst Pharmaceuticals	-40.90%	-86.89%	66.37%
Silence Therapeutics	-8,943.86%	-106.94%	-47.99%

Summary

BioCryst Pharmaceuticals beats Silence Therapeutics on 9 of the 17 factors compared between the two stocks.

Get Silence Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SLN vs. The Competition

Export

Metric	Silence Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$638.12M	$3.99B	$7.28B	$12.72B
Dividend Yield	N/A	3.64%	2.54%	10.79%
P/E Ratio	-10.55	11.76	271.35	24.06
Price / Sales	1,034.59	1,302.10	605.78	77.99
Price / Cash	N/A	44.94	29.03	36.90
Price / Book	10.20	17.24	11.18	6.39
Net Income	-$88.61M	-$22.72M	$3.46B	$348.39M
7 Day Performance	-6.15%	2.86%	1.95%	1.06%
1 Month Performance	22.21%	9.66%	7.28%	5.22%
1 Year Performance	151.72%	54.43%	24.58%	16.09%

Silence Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SLN Silence Therapeutics	3.0244 of 5 stars	$13.47 +1.5%	$53.50 +297.3%	+148.0%	$638.12M	$615K	N/A	100
SLS SELLAS Life Sciences Group	0.823 of 5 stars	$13.10 +0.8%	$10.00 -23.7%	+709.4%	$2.65B	N/A	N/A	10	Options Volume
KOD Kodiak Sciences	2.7542 of 5 stars	$40.66 -0.8%	$48.14 +18.4%	+275.8%	$2.54B	N/A	N/A	90
RARE Ultragenyx Pharmaceutical	3.4346 of 5 stars	$25.49 -2.4%	$57.82 +126.8%	-13.3%	$2.51B	$673M	N/A	1,371	Positive News Analyst Forecast
NKTR Nektar Therapeutics	2.9091 of 5 stars	$73.74 +1.5%	$150.00 +103.4%	+173.8%	$2.49B	$54.59M	N/A	220	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SLN) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Silence Therapeutics (SLN) Competitors

SLN vs. SLS, KOD, RARE, NKTR, and BCRX

How does Silence Therapeutics compare to SELLAS Life Sciences Group?

Summary

How does Silence Therapeutics compare to Kodiak Sciences?

Summary

How does Silence Therapeutics compare to Ultragenyx Pharmaceutical?

Summary

How does Silence Therapeutics compare to Nektar Therapeutics?

Summary

How does Silence Therapeutics compare to BioCryst Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLN vs. The Competition

Silence Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Silence Therapeutics (SLN) Competitors

SLN vs. SLS, KOD, RARE, NKTR, and BCRX

How does Silence Therapeutics compare to SELLAS Life Sciences Group?

Is SLS or SLN more profitable?

Does the media favor SLS or SLN?

Which has higher valuation & earnings, SLS or SLN?

Do analysts recommend SLS or SLN?

Which has more risk & volatility, SLS or SLN?

Do insiders and institutionals have more ownership in SLS or SLN?

Summary

How does Silence Therapeutics compare to Kodiak Sciences?

Do analysts recommend KOD or SLN?

Do institutionals & insiders have more ownership in KOD or SLN?

Does the media favor KOD or SLN?

Is KOD or SLN more profitable?

Which has preferable earnings and valuation, KOD or SLN?

Which has more volatility & risk, KOD or SLN?

Summary

How does Silence Therapeutics compare to Ultragenyx Pharmaceutical?

Which has better earnings & valuation, RARE or SLN?

Which has more volatility & risk, RARE or SLN?

Do analysts rate RARE or SLN?

Do insiders and institutionals believe in RARE or SLN?

Does the media prefer RARE or SLN?

Is RARE or SLN more profitable?

Summary

How does Silence Therapeutics compare to Nektar Therapeutics?

Which has more volatility and risk, SLN or NKTR?

Which has better earnings & valuation, SLN or NKTR?

Do insiders & institutionals believe in SLN or NKTR?

Does the media refer more to SLN or NKTR?

Is SLN or NKTR more profitable?

Do analysts rate SLN or NKTR?

Summary

How does Silence Therapeutics compare to BioCryst Pharmaceuticals?

Which has more risk and volatility, BCRX or SLN?

Do insiders & institutionals believe in BCRX or SLN?

Which has higher earnings and valuation, BCRX or SLN?

Does the media prefer BCRX or SLN?

Do analysts recommend BCRX or SLN?

Is BCRX or SLN more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLN vs. The Competition

Silence Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools